NIKKEI 225
38,775.21 +285.04 (+0.74%) HANG SENG
18,404.83 -20.13 (-0.11%) CRUDE OIL
74.49 +0.42 (+0.57%) GOLD FUTURES
2,387.80 +12.30 (+0.52%) DOW
38,807.33 +96.04 (+0.25%) Bitcoin GBP
55,367.39 -150.69 (-0.27%)
Novartis AG (NOVNZ.XC)
| Previous close | 92.71 |
| Open | 93.47 |
| Bid | 94.45 x 0 |
| Ask | 94.47 x 0 |
| Day's range | 93.47 - 94.57 |
| 52-week range | 79.19 - 94.57 |
| Volume | |
| Avg. volume | 527,963 |
| Market cap | 192.737B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 24.10 |
| EPS (TTM) | 3.92 |
| Earnings date | 18 Jul 2024 |
| Forward dividend & yield | 3.30 (3.49%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
ZacksWhy Novartis (NVS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ZacksNovartis (NVS) Reports Positive Long-Term Data on CSU Drug
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Globe NewswireNovartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs. investigator-selected SoC TKIs (imatinib, nilotinib, dasatinib and bosutinib) (67.7% vs. 49.0%) and imatinib alone (69.3% vs. 40.2%)1 Scemblix also demonstrated a favorable safety and tolerability profile vs. imatinib and 2G TKIs, with fewer grade ≥3 AEs, dose adjustments, and half the rate of AEs leading to tr
